Invenirex appoints Chair to help guide roll-out of AI diagnostic platform

InvenireX – the Newcastle-based biotech company that aims to disrupt the market for PCR laboratory tests  – has appointed Alastair Carrington as Non-Executive Chairman.

Daniel Todd (Co-Founder and CEO of InvenireX) and Alastair Carrington (Non-Executive Chairman)

Alastair brings a wealth of experience in commercial strategy and leadership, particularly in the deep tech sector, to help position InvenireX at the forefront of the diagnostics market. During his career, he has held senior roles with companies including Cambridge-based Expedeon and Stirling-based Integrated Graphene and is currently CEO of Newcastle-based Atelerix.

Alastair’s appointment follows a recent £500,000 investment in InvenireX by DSW Ventures and XTX Ventures and comes as the company prepares to launch its first commercial pilot studies.

Doug Quinn, partner at DSW Ventures, said: “Alastair’s appointment is another key step for InvenireX. His experience in bringing R&D innovations to market is exactly what the company needs to help guide it through the commercialisation process, identify lucrative opportunities, and ensure a smooth roll-out.”

Daniel Todd, co-founder and CEO of InvenireX, added: “Having Alastair on board is a game changer for us. His expertise will be invaluable in helping us navigate the complex terrain of launching a disruptive new technology. With his guidance, we can avoid common pitfalls and successfully introduce our novel diagnostic solutions to the market.”

Responding to his new role, Alastair commented: “I am truly impressed by the dedication and speed of innovation at InvenireX. The team’s ambition to disrupt and enhance scientific understanding through single nucleotide detection is not just exhilarating; it’s also profoundly important. It’s an exciting challenge to help steer such a dynamic company from a start-up to become a major disruptor in the industry.”

InvenireX aims to revolutionise the field of molecular diagnostics molecular analysis with its advanced AI and ‘nanite’ technology. Its AI-driven platform has potential for ultra-early disease detection, personalised medicine and environmental monitoring.